Interview with Marcin Hanczaruk, General Manager, Ferring Pharmaceuticals Poland
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Address: ul. Bonifraterska 17
00-203 Warszawa
Poland
Tel: +48 22 246 0680
Ferring Pharmaceuticals is a research-driven biopharmaceutical company devoted to identifying, developing and marketing innovative products in the fields of reproductive health, urology, gastroenterology, endocrinology and osteoarthritis.
The company’s research activities and products are connected by a common thread focused on the provision of tailored treatments that work on the body’s own terms to enable doctors to combat numerous diseases and medical conditions.
The company has gained international recognition over the last 20 years for the creation of inventive medications that improve the quality of life of children and adults all around the world.
Ferring has its own production facilities in several European countries, in South America, Israel and China. With the acquisition of Bio-Technology General in 2005, it has capabilities in recombinant biotechnology as well as more traditional pharmaceutical manufacturing.
Ferring’s marketing, medical services and sales teams, led by corporate headquarters in Saint-Prex, Switzerland, operate from more than 45 countries and employ more than 3700 people throughout the world, while treatments are available in more than 70 countries. This expansion has allowed Ferring to maintain a double digit annual growth rate over the last two decades.
Ferring’s R&D projects complement Ferring’s product portfolio and will add a new generation of products to some of the company’s most successful specialty brands. R&D facilities are located in Denmark, Israel and California, USA.
Ferring is committed to a future where it will continue to provide new and innovative medicines by utilising existing and acquired skills and the development of pioneering technologies and, where necessary, through partnerships with academic institutes and other companies.
For fifty years, we have been at the forefront of innovation in the field of naturally occurring human peptides. We have developed treatments in areas that span the human life cycle, including: reproductive health, endocrinology, gastroenterology and urology:
Ferring’s infertility treatments give infertile couples the chance to have babies
In obstetrics, Ferring helps premature children to be born healthy and without handicaps
With treatments in endocrinology, Ferring gives children the chance to overcome growth deficiencies
Ferring’s inflammatory bowel disease (IBD) treatments enable young adults with IBD to live a normal life
In urology, Ferring’s treatment for nocturia and bedwetting helps adults and children to an undisturbed night’s sleep
Ferring’s testosterone replacement treatment improves the key symptoms of low testosterone, reduces fat and improves muscle strength and mood
Ferring’s hormonal therapy for prostate cancer offers a new treatment option to men with an advanced hormone-dependent cancer
Ferring’s strength is our extensive knowledge of peptides and the role they play in the human body.
As we are just entering 2011, could you share with us the results of the Polish affiliate in 2010? 2010 was for Ferring Poland a year of reconstruction. The affiliate…
Maciej Wieczorek, president of Celon Pharma, discusses the award-winning success of the 2016 IPO on the Warsaw stock exchange and the opportunities this has opened up, as well as investment…
Iwona Skrzekowska-Baran, owner and CEO of Pharm&Med, a young, exciting Polish consultancy that is helping clients to transform evidence, policy insights, and market intelligence into effective market access strategies. She…
Leonardo Maffioli, senior marketing and commercial manager of the fertility and endocrinology division of IBSA, discusses the story of IBSA Poland and the potential of the Polish market for the…
Jacek Glinka, president of Mylan Europe, and Tomasz Buczek, country manager of Mylan Poland, discuss the intricate dynamics of the European and Polish pharmaceutical ecosystem and the steps required to…
Witold Włodarczyk, director general of Polmed (Polish chamber for medical devices), discusses the Polish medical device landscape and the policy surrounding the sector, especially the proposed 2016 reimbursement act. Furthermore,…
Krzysztof Łokaj, general manager of Chiesi Poland, discusses the positioning of the company as they become the absolute leaders in the respiratory field, driven by Fostex® and soon Trimbow®. Furthermore,…
Dariusz Głogowski, country manager of Alvogen Poland, discusses his successful strategy to introduce biosimilars onto the Polish market and the nation’s moves to reward this new wave of generics. Furthermore,…
Agnieszka Grzybowska-Zalewska, general manager of Sanofi Genzyme Poland, reflects on the company’s stable growth over the last few years and the market access challenges they have encountered along the way.…
Dr. Wolfgang Wagner, regional director of Wörwag EU and CEE, highlights the ongoing process of the company to integrate itself within each respective healthcare community so patients can receive better…
Paweł Przewięźlikowski, CEO of Selvita, the largest biotech company between Germany and India, discusses the first-in-class and pioneer Polish molecule, SEL24, and the future game changing molecule, SEL120 – the…
Mieczysław Wośko, president and founder of Polfarmex, a leading Polish company, discusses the key factors behind the enterprise’s successful growth and the movement towards R&D to create their own treatments.…
Michał Mieszkowski, general manager of Angelini Poland, discusses the strategic significance of Poland for the company, as the third largest affiliate within the global company, the company’s impressive product portfolio…
See our Cookie Privacy Policy Here